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ARTICLE
NDP52 activates nuclear myosin VI to enhance
RNA polymerase II transcription
Natalia Fili1, Yukti Hari-Gupta1, Ália dos Santos1, Alexander Cook1, Simon Poland2, Simon M. Ameer-Beg 2,
Maddy Parsons2 & Christopher P. Toseland 1
Myosin VI (MVI) has been found to be overexpressed in ovarian, breast and prostate can-
cers. Moreover, it has been shown to play a role in regulating cell proliferation and migration,
and to interact with RNA Polymerase II (RNAPII). Here, we ﬁnd that backfolding of MVI
regulates its ability to bind DNA and that a putative transcription co-activator NDP52 relieves
the auto-inhibition of MVI to enable DNA binding. Additionally, we show that the
MVI–NDP52 complex binds RNAPII, which is critical for transcription, and that depletion of
NDP52 or MVI reduces steady-state mRNA levels. Lastly, we demonstrate that MVI directly
interacts with nuclear receptors to drive expression of target genes, thereby suggesting a link
to cell proliferation and migration. Overall, we suggest MVI may function as an auxiliary
motor to drive transcription.
DOI: 10.1038/s41467-017-02050-w OPEN
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yosins are molecular motors that perform vital roles in
a plethora of cellular processes. Myosin VI (MVI) is a
unique member of the myosin family with the ability to
move towards the minus end of actin ﬁlaments1. This property
enables MVI to be involved in cell migration, endocytosis, exo-
cytosis and transcription2, 3. The functional diversity of MVI
relies on its tightly regulated association with various binding
partners. Given its multi-potent nature, malfunction of MVI leads
to various diseases including cardiomyopathy, deafness and
cancer4–7.
MVI comprises a motor domain, followed by a neck region
consisting of a unique insert, which confers the reverse direc-
tionality, and an IQ domain (Fig. 1a). The N-terminal tail domain
(NMVITAIL) contains two structural domains a three-helix-bundle
(amino acids 835–916)8 (3HB) and a single-alpha-helix (amino
acids 942–978) (SAH)9. The C-terminal tail domain contains the
globular cargo binding domain (CBD). In addition, two regions
within the tail can be alternatively spliced resulting in a 31-
residue insertion (large insert, LI) before the CBD, and/or an 8-
residue insertion in the CBD (small insert, SI). This leads to four
splice isoforms, the non-insert (NI), SI, LI and LI + SI10.
The CBD confers speciﬁcity for cargo through its ability to
bind partners, such as Dab2, GIPC and NDP52, at two motifs
WWY and RRL11–13. NDP52 was initially identiﬁed in the
nucleus14, 15 but has been better characterised in cell adhesion
and autophagy11, 16. Intriguingly, NDP52 shares 70% sequence
identity to its family member CoCoA, a known transcription co-
activator, which suggests a potential role in transcription17.
MVI is overexpressed in aggressive cancers including ovarian,
breast and prostate5, 7, 18, and depletion of MVI leads to
decreased cell motility and/or proliferation18–20. As MVI is
known to have roles in gene expression3, 21, it is possible that this
is linked to the nuclear role of MVI.
To shed light upon this hypothesis, here we have explored the
potential functions of nuclear MVI. The association of MVI with
RNAPII is dependent upon its DNA binding, which is in turn
regulated by co-activator NDP52. This alters the MVI oligomeric
and mechanical properties. Moreover, MVI interacts with nuclear
receptors for speciﬁc gene targeting. We suggest MVI is an
auxiliary motor for RNAPII to drive gene expression.
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Fig. 1 Myosin VI is distributed throughout the nucleus. a Cartoon depiction of the MVI domains and key features discussed in the text. b
Immunoﬂuorescence staining against MVI (magenta) and DNA (cyan) in HeLa cells and isolated nuclei (see Supplementary Fig. 1 for nuclei images).
Arrows highlight ﬁlamentous structures within the nucleus. Images were acquired at the mid-point of the nucleus. Scale bar 10 μm for whole images and 1
μm for inserts. c Western blot against MVI following HeLa cell fractionation. Tubulin and lamin B are used as cytoplasmic and nuclear markers,
respectively. d Representative images of transiently expressed NI- and LI-GFP-MVI in HeLa cells combined with DNA staining (cyan) (Supplementary
Fig. 3). Images acquired as in B. e Pull-down of recombinant MVI using a 500 bp DNA substrate. f Plot of band intensities normalised to the input sample
(5 μM). Errors bars represent SEM from three independent preparations. (**p< 0.001 by two-tailed t-test between presence and absence of DNA)
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Results
Myosin VI non-insert isoform is recruited to the nucleus.
Before exploring the nuclear role of MVI, we ﬁrst assessed its
distribution. Immunoﬂuorescence on both HeLa cells, and iso-
lated nuclei, and cell fractionation conﬁrmed an endogenous
nuclear population (Fig. 1b, c and Supplementary Movies 1–5),
consistent with previous reports3. MVI was distributed
throughout the nucleus, although occluded from the nucleoli.
MVI decorated punctate and ﬁlamentous structures, which
occasionally interconnected forming small networks (Fig. 1b,
Supplementary Movies 1 and 2). To explore the nature of these
structures, we tested the possibility of MVI localising on nuclear
actin ﬁlaments. Dense nuclear actin cables were absent in whole
cells (Supplementary Fig. 2a and Supplementary Movie 6), but a
sparse actin network may be present. However, the lack of
staining in the isolated nuclei (Supplementary Fig. 2a) suggested
that MVI structures are not actin-based but may represent MVI
bound to chromatin.
Recently, it was shown that several cancers only express the NI
isoform22, as is the case in HeLa cells. Yet, it has not been shown
if the isoform selection and nuclear localisation are functionally
linked. To address whether such a relationship exists, we
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Fig. 2 DNA binding by myosin VI. a, b Fluorescence anisotropy titrations of MVI domains against a 40 bp ﬂuorescein amidite (FAM)-DNA (50 nM). Data
ﬁtting was performed as described in Methods (Kd± SEM n= 3 independent experiments). Due to the low binding afﬁnity, Motor1-814 could not be ﬁtted
using the model. c Cartoon depicting the secondary structure within the CBD. Binding partner motifs and known lipid binding sites are highlighted along
with three predicted clusters of DNA binding. Black lines represent residues predicted to be involved in DNA binding. Sequence alignment shows the
conservation of sites B and C. d Structure of CCBD with site B (red), C (blue) and WWY motif (green) (PDB:2KIA54). e, f Fluorescence anisotropy titrations
of CBD constructs, as performed in a
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compared the intracellular distribution of transiently expressed
EGFP-NI- and LI-MVI. EGFP-NI-MVI had a similar distribution
to the endogenous protein (Fig. 1d). Strikingly, EGFP-LI-MVI
localisation was restricted to the cell periphery (Fig. 1d and
Supplementary Fig. 3a, b).
The LI has been recently shown to encode an alpha-helix that
blocks the RRL-motif, establishing an isoform-speciﬁc regulation
for the interactions with binding partners22. A point-mutation
within the LI, namely M1062Q, disrupts this process. As
expected, EGFP-LI-MVI(M1062Q) had a similar cellular dis-
tribution to the NI isoform (Supplementary Fig. 3c). Taken
together, these data demonstrate that splicing regulates the
recruitment of MVI into the nucleus, likely by controlling access
to the RRL-motif.
Myosin VI binds DNA through its CBD. The presence of MVI
throughout the nucleus and its known association with RNAPII
leads to the intriguing possibility that this myosin might bind to
chromatin. BindN23 predicted sites for interaction with DNA are
highlighted throughout MVI, with higher frequency within its tail
(Supplementary Table 1 and Fig. 2b). To establish if MVI can
interact with DNA, we used a DNA pull-down assay. Recombi-
nant NI-MVI was isolated in complex with the linear DNA
(Fig. 1e).
To further explore this interaction in a quantitative manner, we
utilised ﬂuorescence anisotropy. MVI was titrated against DNA
revealing a relatively weak binding (Fig. 2a and Supplementary
Table 2). To identify the regions within MVI that mediate DNA
binding, the titrations were also performed using isolated
domains. Our results demonstrate that the DNA-binding ability
is restricted to the MVITAIL (Fig. 2a). Intriguingly, the isolated
CBD displayed a 25-fold higher afﬁnity for DNA (Fig. 2b). The
CBD bound promiscuously to single-stranded and double-
stranded DNA of varying composition, although weaker for
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Fig. 3 Regulation of myosin VI backfolding. a FRET titration of NMVITAIL against CBD (1 μM) or CBD(W1221A) in the presence of DNA, or NDP52, at 10 μM.
Data ﬁtting was performed as described in Methods. NDP52 and CBD(W1221A) data are plotted as disconnected points due to low signal change. See
Supplementary Fig. 4a–c for raw intensity data. b Representative ﬂuorescence spectra of 2 μM GFP-MVITAIL-RFP± 15 μM NDP52. c FLIM measurements of
in vivo MVI conformational dynamics. Above, schematic showing the constructs. Left, GFP intensity and lifetime images. Right, intensity and lifetime
images of the biosensor. Lifetime (τ) is represented by a pseudocolor scale. Scale bar is 20 μm. d Pull-down of CBD by His-tagged NMVITAIL both at 10 μM
± 20 μM 40 bp DNA. P and S represent pellet and supernatant fractions. e Fluorescence anisotropy titrations of MVI domains against a 40 bp FAM DNA,
as performed in Fig. 2a
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substrates <20 bases (Supplementary Fig. 2c). The N-terminal
MVITAIL (NMVITAIL814-1060) also bound DNA, but not as
strongly as the CBD (Fig. 2b). A summary of the kinetic
parameters is presented in Supplementary Table 2.
To understand the DNA-binding mechanism, we used pre-
steady-state measurements. Here, the CBD had a four-fold higher
association rate constant than full-length (FL) protein, while the
dissociation rate constant was essentially unchanged (Supple-
mentary Fig. 2d and Supplementary Table 3). This indicated that
once binding is achieved, the stability of the bound state is the
same in both constructs. Therefore, we conclude that MVI binds
DNA through its CBD and this binding is impeded in the FL-
MVI, possibly due to the adopted conformation.
DNA binding occurs through two adjacent loops in the CBD.
We decided to identify the sites conferring the DNA-binding
ability. Based on predictions, we distinguished three clusters—
sites A–C (Fig. 2c) in the MVITAIL. We generated various
MVITAIL mutants and truncations, and assessed their DNA-
binding potential. Mutagenesis of site A, which corresponds to a
known PIP2 lipid-binding site
13, perturbed lipid binding (Sup-
plementary Fig. 2e), but only partially affected DNA interactions
(Fig. 2e). This suggested that binding occurs through sites B and
C. This was further reinforced when we tested two truncations of
CBD, NCBD1060-1120 (containing Site A) and CCBD1121-1253
(containing sites B and C) (Fig. 2e). NCBD displayed a con-
siderably reduced DNA binding, while the CCBD was indis-
tinguishable from the entire CBD domain. Sites B and C are
located on two highly conserved adjacent loops which likely form
a single binding surface in close proximity to the WWY motif
(Fig. 2d). Alanine mutagenesis of either site reduced DNA
binding (Fig. 2f), indicating that both sites are required for efﬁ-
cient interaction with the DNA. Mutagenesis of both sites
destabilised the domain thereby preventing the measurements.
Backfolding of myosin VI regulates its ability to bind DNA. As
shown above, although the CBD binds DNA efﬁciently, the
binding ability of the FL protein is impeded. This suggests that
DNA binding is regulated. MVI is suggested to regulate its
activity through backfolding24–26. We therefore explored if such a
mechanism regulates DNA association. Having already estab-
lished that the MVITAIL displayed similar DNA binding beha-
viour as FL-MVI (Fig. 2a), we hypothesised that, if backfolding
occurs, the tail should fold upon itself. Hence, we assessed whe-
ther the CBD and the NMVITAIL can form an interaction. To this
end, a FRET-based assay was employed by titrating Alex-
a555-NMVITAIL to FITC-CBD. A signiﬁcant change in FRET was
detected, indicating that the two domains are in close proximity
(Fig. 3a, dissociation constants are summarised in Supplementary
Table 4). A ﬂuorescence anisotropy assay conﬁrmed this inter-
action (Supplementary Fig. 4d). To further conﬁrm the ability of
the MVITAIL to backfold, we used a dual-labelled construct, GFP-
MVITAIL-RFP. Here, FRET would report upon the folded state.
Indeed, a small FRET signal was observed (Fig. 3b), indicating a
degree of backfolding.
While we have explored how backfolding occurs in vitro, it is
unknown if this occurs in vivo. To explore the in vivo
conformation dynamics, we used ﬂuorescence lifetime imaging
(Fig. 3c). A GFP–MVI–RFP construct was used as a conformation
reporter in HeLa cells. Indeed, two populations were observed in
a high and low FRET state, indicating that backfolding does occur
in vivo.
The NMVITAIL–CBD complex represents the folded form,
where we propose the DNA-binding sites are occluded. To test
whether backfolding and DNA binding are mutually exclusive, we
performed the in vitro FRET measurements with a pre-formed
CBD–DNA complex. There was a lack of interaction between the
NMVITAIL and CBD–DNA complex, suggesting that the presence
of DNA prevented backfolding (Fig. 3a). To further conﬁrm our
results, all the above interactions were also assessed using pull-
down assays (Fig. 3d). The CBD co-puriﬁed with NMVITAIL,
whereas the presence of DNA sequestered the CBD. Taken
together, these data demonstrate that DNA binding is regulated
through intra-molecular backfolding.
Calcium does not regulate myosin VI backfolding. A
mechanism controlling the open/closed state of the tail could be
regulated by cofactors such as ATP, actin and Ca2+. However,
DNA binding by MVI was not enhanced in their presence
(Supplementary Fig. 4f), even though Ca2+-Calmodulin was
recently reported to regulate the backfolding of MVI24. Pull-down
assays in the presence of CBD, with and without calcium were
performed using two truncations Motor1-814 and Motor1-1060,
containing 1 or 2 calmodulin binding sites, respectively. All
constructs containing the motor domain were co-expressed with
calmodulin. Supplementary Fig. 4g shows that both constructs
associated with the CBD. Whilst expected for the Motor1-1060,
binding to Motor1-814 suggested the CBD also forms extensive
contacts with the motor domain, which is consistent with SAXS
data by Spink26. However, Ca2+ had no discernible impact upon
these interactions, in contrast to Batters24. This discrepancy
could be attributed to the fact that, in their work, the pull-down
experiments, which were assessing the ability of the tail to
backfold, were only performed in the absence of Ca2+. Instead,
only far-dot western blots were performed in the presence of Ca2
+. However, those experiments were addressing the effect of Ca2+
on the interaction of the tail with calmodulin, rather than the
backfolding of the tail itself.
Interaction with NDP52 regulates myosin VI backfolding.
Having established that ATP, actin and Ca2+ do not regulate MVI
backfolding, we explored the possibility that a binding partner
could be an alternative regulator. The adaptor binding site, the
RRL-motif, is situated away from sites B to C and, therefore, it is
unlikely to perturb DNA binding. One such protein, which binds
this motif, is NDP52. To address whether NDP52 is an MVI
regulator, the FRET assay between the NMVITAIL and the CBD
was repeated following pre-incubation of the CBD with NDP52.
Similar to DNA, NDP52 sequestered the CBD preventing the
interaction between the two domains (Fig. 3a). Moreover, addi-
tion of excess of NDP52 in our GFP–MVITAIL–RFP reporter
resulted in the loss of the FRET signal (Fig. 3b), indicating the
tail’s unfolding.
For NDP52 to elicit unfolding of MVI, it would need to disrupt
sites within the protein that form a stable interaction, such as the
recently proposed W122127. Mutagenesis lead to an increase in
actin binding, which was attributed to unfolding of MVI. Using
the FRET assay, we observed that CBD(W1221A) failed to bind to
NMVITAIL (Fig. 3a), conﬁrming that the mutation likely leads to
the unfolding of the protein. Interestingly, the MVITAIL(W1221A)
was able to bind DNA, similar to the CBD (Fig. 3e), indicating
that the adopted conformation enhances the ability of MVI to
bind DNA. Taken together, our data suggest a model, whereby
NDP52 triggers a conformational change of MVI leading to an
unfolded state with enhanced DNA binding ability.
NDP52 is a nuclear binding partner of myosin VI. While cal-
cium and ATP are important regulators that ﬁne-tune motor
function, we show that NDP52 can trigger unfolding of MVI by
relieving the autoinhibition between the CBD and the N-terminal
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tail/motor domain. In order to unravel the physiological relevance
of our in vitro ﬁndings and explore the role of NDP52, we
decided to characterise NDP52 and its interaction with MVI.
NDP52 consists of a SKICH domain followed by a long coiled-
coil and two Zinc ﬁnger domains that may confer the ability to
bind DNA (Fig. 4a). Indeed, we observed that NDP52 can bind
DNA (Supplementary Fig. 5a) with high afﬁnity. This binding
precluded the use of this protein in our DNA-binding assays
because the contribution by MVI would be masked by that of
NDP52. However, together with MVI’s ability to bind DNA and
its nuclear distribution, this ﬁnding pointed towards the direction
of a potential partnership between NDP52 and MVI in the
nucleus.
We observed the distribution of NDP52 in HeLa cells using
immunoﬂuorescence and cell fractionation. Endogenous NDP52
was distributed throughout the cytoplasm as well as into the
nucleus, similar to MVI (Fig. 4b, c). The nuclear pool of NDP52
decorated punctate structures, which were, in places, intercon-
nected into small ring-like networks (Supplementary Movie 7).
Similar distribution was also observed in isolated HeLa nuclei,
suggesting that these structures are stable (Fig. 4b and
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Fig. 4 NDP52 is a nuclear myosin VI binding partner. a Cartoon and structural model depicting NDP52 domains as mentioned in the text. b
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Immunoﬂuorescence staining against NDP52 (green), MVI (magenta) and DNA (cyan), as performed in Fig. 1b. Insert depicts co-localising foci. Scale bar
10 μm for whole images and 1 μm for inserts. Pearson’s coefﬁcient is shown for HeLa and nuclei (Supplementary Fig. 5b). Error bars represent SEM from 10
images
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02050-w
6 NATURE COMMUNICATIONS | 8:  1871 |DOI: 10.1038/s41467-017-02050-w |www.nature.com/naturecommunications
Supplementary Movie 8). As with MVI, this may represent
binding to chromatin.
To characterise the interaction between MVI and NDP52, we
initially performed an in vitro FRET assay using FITC-MVITAIL
and Alexa555-NDP52. NDP52 was titrated against MVITAIL
containing various mutants of the RRL-site, as well as a LI-
MVITAIL (Fig. 4d, e and Supplementary Table 4). Wild-type
MVITAIL had a low micromolar afﬁnity for NDP52. When we
mutated the ﬁrst arginine (ARL), there was essentially no effect
upon NDP52 binding. Conversely, mutation of the second
arginine (RAL) abolished the interaction, whereas removal of
the leucine (RRA) led to a 10-fold decrease in afﬁnity. Finally, the
presence of the LI reduced binding by 4-fold.
This was complemented by pull-down assays using recombi-
nant fragments of CBD as bait to search nuclear extracts for
interactions with native nuclear NDP52 (Fig. 4f). As expected,
binding occurred within the RRL-containing NCBD. In addition,
whereas the presence of the LI compromised the binding to
NDP52, this effect was rescued by the M1062Q mutant. Overall,
these data suggest that MVI can associate with the nuclear pool of
NDP52. Indeed, when we immuno-stained HeLa cells (Fig. 4g)
against the endogenous MVI and NDP52, we observed that the
two proteins partially colocalised within the nucleus: they
occasionally localised on the same punctate and ﬁlamentous
structures, sometimes as part of the same local networks. This
partial co-localisation is consistent with the micromolar dissocia-
tion constant, and is indicative of a dynamic interaction. The co-
localisation was also dependent upon the MVI isoform whereby
the LI displayed the lowest colocalisation (Supplementary Fig. 5c,
d). Therefore, taking all data together, we conclude that NDP52 is
a nuclear partner of MVI.
Interaction with NDP52 mediates myosin VI dimerisation. We
have revealed how NDP52 and MVI interact in the nucleus to
bring about unfolding of MVI, enabling DNA binding. However,
this may not be the only consequence of this interaction. The
oligomeric state of MVI has long been a controversial subject,
along with the possible roles of partners25, 28. MVI contains a
potential dimerisation site through a predicted coiled-coil29, just
before the CBD. It is probable that this motif is also masked in the
folded conformation, in a similar manner to the DNA-binding
site. Therefore, the NDP52-induced unfolding of MVI could
enable dimerisation, forming a highly processive motor.
To explore this hypothesis, we ﬁrstly assessed the ability of
MVI to dimerise, using an actin pull-down assay. Here, MVI
pellets when bound to actin, causing co-sedimentation of proteins
that MVI is in complex with. Therefore, if the MVITAIL is
incubated with FL-MVI and a heterodimer is formed, the
MVITAIL will pellet with the MVI-actin complex. Indeed,
MVITAIL was observed in the pellet (Supplementary Fig. 6a, b).
The bound molar concentration of MVITAIL was limited by the
sub-stoichiometry concentration of MVI. When performed with
higher MVI concentrations, a greater amount of MVITAIL co-
sedimented. Overall these data show that MVI can dimerise,
albeit inefﬁciently.
To quantify this process, we performed a FRET assay, whereby
two pools of MVITAIL were labelled, one with FITC and the other
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with Alexa555. Titrations revealed a weak association (Fig. 5a, b
and Supplementary Fig. 7d), consistent with our pull-down
results. Interestingly, upon addition of excess NDP52, a large
change in FRET was observed, indicating the formation of a
stable dimer. Moreover, while the presence of DNA could not
yield dimerisation, it did not prevent it from occurring in the
presence of NDP52. This observation highlights an important
distinction between DNA and NDP52; while both can sequester
the CBD, only NDP52 can disrupt the interaction with the rest of
the tail and promote unfolding.
Dimerisation is an intrinsic property of the myosin VI. To
determine whether dimerisation is driven by the coiled-coil
domain located in the NMVITAIL, the FRET assay was repeated
using NMVITAIL and the CBD. A signiﬁcant FRET change was
observed for NMVITAIL, which was independent of its ability to
bind NDP52 (Fig. 5b and Supplementary Fig. 7f). This conﬁrmed
the innate ability of MVI to dimerise within this region. The CBD
did not dimerise, irrespective of NDP52 (Fig. 5b and Supple-
mentary Fig. 7e, g). NDP52, and many other partners, are likely
dimers themselves, and therefore, it has long been thought that
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MVI dimerisation is driven through its partner, rather than being
innate to itself. When sub-stoichiometric amounts of NDP52
were used, upon saturation of NDP52 with CBD, a FRET change
was observed (Supplementary Fig. 7g). This is likely to be due to
the binding of two CBD monomers to each subunit of NDP52.
This indirect dimerisation was not observed with the MVITAIL
because NDP52 was in excess (Fig. 5a). However, when sub-
stoichiometry NDP52 was used, a breakpoint in the titration was
observed at a concentration equal to that of NDP52 (Supple-
mentary Fig. 7h). This was followed by a linear increase in FRET,
which is indicative of further binding, but in a different manner
to the one observed in excess of NDP52. Therefore, our data
suggest that both dimerisation mechanisms are possible (Fig. 5d),
opening the intriguing possibility that localised partner con-
centration could regulate different complex formats, each with a
potentially different role.
Partner induced dimerisation regulates myosin VI motility.
Dimerisation can alter the mechanical properties of the protein,
which translates into changes in the motor behaviour. The
steady-state ATPase kinetics of MVI revealed a 50% reduction in
the rate constant following addition of NDP52 (Supplementary
Fig. 6c), but no change in the presence of DNA. This is typical of
molecular gating, whereby each head of the dimer alternates ATP
hydrolysis30. Moreover, the rate constant for FL-MVI in the
presence of NDP52 was essentially identical to that of the MVI
truncation without CBD (Motor1-1060). We propose this construct
would fail to backfold but could dimerise through the coiled-coil.
To explore the mechanical consequences of MVI dimerisation,
sliding ﬁlament motility assays were performed (Fig. 5c).
Antibodies to the MVITAIL are used to immobilise MVI in the
correct orientation, in order to enable translocation of actin
ﬁlaments. This approach resulted in an increased velocity from
40–50 to 90 nm s−1. However, antibodies were not required if
MVI was pre-incubated with NDP52. Here, two populations were
observed with velocities at 50–60 and 90 nm s−1, which was
dependent upon the NDP52 concentration (Supplementary
Fig. 6d). We suggest this corresponds to apo- and NDP52-
bound MVI, respectively. As we have shown, MVI exists in a
folded conformation, where it would be unlikely to generate
efﬁcient motility, as revealed by the low velocity population.
However, NDP52 unfolds MVI, inducing the mechanical
activation of the motor.
Taking all our data together, we propose the following model
(Fig. 5d): NDP52 initially associates with MVI in its folded state.
This triggers unfolding of the protein and subsequent recruitment
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of a second myosin. Dimerisation could occur through two
mechanisms: dimerisation of two MVI monomers around a single
partner dimer, or dimerisation of two myosin molecules, each
bound to a different partner molecule.
The nuclear role of NDP52 as a transcription regulator. Based
upon its similarity to transcription co-activator CoCoA and its
binding to MVI, we explored if NDP52 partners MVI in tran-
scription. The distribution of the NDP52 in relation to RNAPII
was examined using immunoﬂuorescence (Fig. 6a, b). NDP52
partially colocalised with RNAPII on punctate structures. More-
over, using recombinant NDP52 as bait in nuclear extracts, we
conﬁrmed that FL-NDP52 formed a complex with RNAPII. This
was further supported by co-immunoprecipitation of RNAPII by
NDP52 from HeLa extracts (Fig. 6c, d).
The MVI-binding site is conserved between NDP52 and
CoCoA, and a pull-down between recombinant proteins revealed
the two form a stable interaction (Fig. 6e).
To further explore the role of NDP52 in transcription, we
performed in vitro transcription assays using the HeLaScribe
extracts. To assess the role of various proteins in transcription, we
used antibody depletion to sequester selected proteins from the
extracts, before performing the transcription assays (Fig. 6f and
Supplementary Fig. 8a, b). As expected, depleting a pool of
RNAPII led to a decrease in transcription. Moreover, depletion of
actin which is known to be bound to the RNAPII complex31, 32,
also decreased transcription. Consistent with previous ﬁndings
under the same conditions3, transcription was decreased to about
25% upon depletion of MVI. Interestingly, a 50% decrease was
observed when NDP52 was depleted, suggesting that this protein
is indeed involved in transcription.
Myosin VI’s interaction with RNA polymerase II. MVI has
previously been associated with sites of active transcription3.
Here, we have illustrated that MVI regulator NDP52 also colo-
calised with RNAPII and enhanced transcription.
Building upon our knowledge of which MVI domains bind
DNA, we explored how these domains correspond to coupling
MVI to the RNAPII complex. We employed a competition assay
to displace the native protein using individual recombinant
domains and then performed in vitro transcription. The CBD
alone was able to displace MVI, leading to a decrease in
transcription in a CBD concentration dependent manner (Fig. 7a).
This effect was speciﬁc to the CBD and required the DNA binding
ability within the domain to fully perturb the reaction. In addition,
mutation of the RRL-motif revealed that successful competition is
likely to be driven by partner association at this location. This was
further supported by the lack of inhibition by the LI-CBD.
Our observation of the CBD competing off the MVI, leading to
a decrease in transcription, indicated that the FL-MVI, is required
for transcription. We tested whether the isolated MVI motor
domain can function as a competitor. Indeed, the motor is a
competitor (Fig. 7a), suggesting that MVI forms a bi-polar
interaction with the RNAPII complex, which is vital for
transcription. The importance of the motor domain was further
conﬁrmed when we used the MVI inhibitor 2,4,6-triiodophenol
(TIP)33 to inhibit the MVI motor activity. This treatment resulted
in a transcription level equivalent to depleting MVI.
We explored how the conformation of MVI, its motor activity
and, more speciﬁcally, actin binding can affect transcription. To
further reinforce our results, we performed rescue assays on
antibody depleted extracts, by adding recombinant proteins. The
addition of FL-MVI led to a slight rescue in transcription
(Fig. 7b). However, when in combination with NDP52, there was
a two-fold increase in transcript production. This observation
highlights that it is an active unfolded state of MVI that
participates in transcription. When we incubated both samples
with F-actin, we observed no increase in transcription. In this
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case, while interactions through the CBD could occur, the motor
was prevented from coupling to RNAPII because it was bound to
F-actin. Therefore, we concluded that the actin binding site of
MVI is required in transcription, possibly by coupling it to the
complex through RNAPII-bound nuclear actin31, 32.
MVI can co-immunoprecipitate RNAPII from HeLa extracts,
as shown previously3 (Fig. 7c). Subsequently, the recombinant
MVI truncations were also tested for their ability to act as bait for
RNAPII in nuclear extracts (Fig. 7c, d). Indeed, their ability to
bind RNAPII was consistent to their ability to inhibit transcrip-
tion. The CCBD showed high RNAPII binding potential, whereas
the NCBD was weak. This suggests that the main coupling factor
to the RNAPII complex is the DNA binding sites of the CCBD,
rather than the RRL motif. However, the LI did not bind to
RNAPII, conﬁrming that the RRL is still required for the
interaction. Moreover, DNA binding is only possible once MVI is
unfolded which is driven by binding partner at the RRL motif.
Overall, we propose a model whereby MVI is coupled to
RNAPII through both motor-actin as well as interactions of the
CBD with binding partners and/or DNA. This bipartite
association to the complex in an active unfolded state enables
MVI to utilise its mechanical ability during transcription to help
drive or anchor the complex (Fig. 7e).
Myosin VI is coupled to gene expression by nuclear receptors.
Here we have shown that MVI and NDP52 have a role in tran-
scription. Given the overexpression of MVI in breast, ovarian and
prostate cancer5, 7, 18, our ﬁndings indicated a possible link
between MVI and the expression of genes under the regulation of
hormone receptors. There is evidence of coupling MVI to the
androgen receptor34. However, this has not been explored for
other hormone receptors, nor has the consequence upon gene
expression been investigated.
To address such an intriguing possibility, we inspected the C
terminus of MVI and identiﬁed an LxxLL nuclear receptor
binding motif. In addition, as shown in Fig. 8a, pull-down assays
with recombinant proteins revealed that there is a direct
interaction between the CBD and the oestrogen receptor (ER).
Moreover, mutation of this LxxLL motif abolished binding.
To explore the role of MVI in transcription of ER regulated
genes, we switched to using ER positive MCF7 cells and monitored
the expression of the ER target genes PS2 and GREB1. Knockdown
of MVI resulted in a speciﬁc 85% and 40% decrease in expression,
respectively (Fig. 8b and Supplementary Fig. 8d), thereby suggesting
a link between receptor binding and MVI’s role in transcription. It
is important to note that MVI knockdown does not lead to a
general decrease in expression. To explore this relationship in a
more general context, we also performed luciferase reporter assays
driven by the ERE (ER response element) reporter. As shown in
Fig. 8c, the stimulatory effect of estradiol is impeded upon a
knockdown of MVI. We therefore suggest MVI may have the
potential to regulate genes under ERE control.
Discussion
Here we have explored the function and regulation of nuclear
MVI. The association of MVI with RNAPII is dependent upon its
ability to bind DNA, which is regulated by putative transcription
co-activator NDP52. NDP52 alters the MVI oligomeric and
mechanical properties. We suggest MVI may function as an
auxiliary motor in transcription, with a bipartite coupling to the
RNAPII complex through NDP52-DNA, as well as RNAPII-
bound actin. Finally, MVI interacts with nuclear receptors for
speciﬁc gene targeting (Fig. 8d). These processes are structurally
conﬁned to the nuclear localising NI isoform, frequently found in
cancer cells.
We have shown how a myosin can directly bind DNA. This
occurs through two sites on the CBD that are inaccessible in FL-
MVI. We observed MVI adopting a folded conformation con-
sistent with previous analysis24, 26, 35. Importantly, we have
provided evidence this occurs in vivo using FLIM. Here we pre-
sent a model whereby binding partners can unfold MVI to expose
these sites. Unfortunately, the direct DNA binding by NDP52
prevented the direct measurement of a partner regulating this
process. Nevertheless, we have revealed a mechanism whereby
NDP52 can unfold MVI. The non-speciﬁc selectivity for substrate
and the relatively weak binding afﬁnity for nucleic acids suggests
that DNA binding is likely to be driven through partners and
their abilities to bind speciﬁc DNA targets.
Here we have deﬁned that activation of MVI occurs through
unfolding to enable both its motility and mechanical work.
However, no change in ATPase activity has been observed. It is
here that the role of Ca2+-calmodulin are likely to participate to
ﬁne-tune the motor activity in order to increase or reduce the
ATPase activity, as required.
Our regulatory mechanism also enabled us to look into MVI
oligomerisation. Here we report that MVI can be both a monomer
and dimer dependent upon binding partner, with the latter con-
trolled by the innate ability of the protein to dimerise. Our model
is in agreement with the previous conclusions28, 36, where it was
proposed that MVI adopts a folded conformation and cargo
bridges two motors, with the close proximity leading to internal
dimerisation37. We found that NDP52 triggered this process, and
it occurred by exposing the dimerisation domain through
unfolding. We suggest dimerisation occurs within the NMVITAIL
(amino acids 814–1060), which is in agreement to the model
proposed by Mukherjea8 where the authors proposed dimerisation
occurring distal to the 3HB between residues 917–942. Moreover,
a later study conﬁrmed this site was necessary for MVI to function
in vivo38 and the SAH domain (residues 842–978) was redundant.
The dissociation constant for dimerisation within the
NMVITAIL is essentially identical to the MVITAIL in the presence
of NDP52, where the latter must be initially unfolded. This
assessment is in agreement with molecular dynamics simulations,
which showed self-association within this region of the
MVITAIL
39. Moreover, our data agree with the experimental evi-
dence from Spink26, whereby the tail was monomeric at 1 μM.
However, at higher concentrations we observed dimerisation
(Fig. 5a and Supplementary Table 4).
We have also explored the nuclear role of NDP52 and linked
the protein to both MVI and RNAPII. Many of our results sug-
gest NDP52 participates in transcription: (i) its DNA-binding
ability, (ii) its high homology to transcription co-activator
CoCoA, (iii) its colocalisation with RNAPII, (iv) its binding to
the RNAPII complex and (v) the observation that its depletion
decreases mRNA yield in vitro. We suggest NDP52 can function
similar to CoCoA. Likewise, we revealed that CoCoA is also a
MVI partner. Further investigation is now required to deﬁne the
nuclear role of NDP52.
MVI was previously linked to transcription initiation and
elongation, whereby depletion reduced transcription3. We have
expanded upon this study, ﬁrstly by dissecting its effect in a
quantitative manner and secondly, by determining the domains
of MVI responsible for its interaction with RNAPII. We have
revealed that the CBD is associated with the RNAPII complex,
requiring both the RRL motif and the DNA-binding sites. We
suggest that NDP52, and/or CoCoA, bind to the RRL motif to
unfold MVI.
Importantly, RNAPII interactions are not limited to the C
terminus of MVI. The motor domain is likely to associate with
RNAPII through actin. Due to the presence of actin on the
RNAPII complex31, 32, it is highly likely for MVI to bind this
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actin population. Whilst the oligomeric state of this actin remains
unknown, it has been suggested that it consists of short poly-
mers40, thereby providing several binding interfaces across the
complex. The importance of the MVI–actin interaction is more
relevant when we used the TIP inhibitor to target the motor
activity. Inhibition resulted in a transcription decrease equivalent
to depletion. Therefore, we conclude that MVI is an active motor
in transcription.
Our ﬁnding that suggests a bipartite association between MVI
and the RNAPII complex would enable mechanical work to be
performed, whereby MVI could either hold the complex in situ,
or act as an auxiliary motor driving RNAPII (Fig. 7e). MVI can
perform both functions, switching between them depending on
the force exerted on it41. We speculate that MVI could help
propel the RNAPII complex, but should the complex encounter a
stall, it could exert a load upon MVI, triggering a switch to a
‘tether mode’ until transcription begins again. Indeed, MVI has
been associated with transcription pause-restart21.
MVI has previously been linked to the androgen receptor (AR),
with evidence for a direct interaction between the two34. We
identiﬁed a nuclear receptor binding motif at the C terminus of
MVI which enabled ER binding, suggesting a wider link to
nuclear receptors beyond the AR. A link between MVI and
nuclear receptors is of particular importance, given their role in
cell proliferation, which is reduced after MVI knockdown18, 20.
We found that MVI knockdown led to a decreased expression of
ER target genes. Moreover, luciferase reporter assays showed that
MVI is involved in regulating expression from ERE promoters.
Therefore, MVI may participate in the activation of ER-driven
gene expression (Fig. 8d), which drives tumour development and
maintains the tumorigenic potential of cells. A wider genomic
study is required to reveal the extent of this effect.
In summary, we have revealed how the motor protein can bind
DNA in a process regulated by NDP52. The binding partner
releases an autoinhibited state, which also enables dimerisation.
This couples MVI to the RNAPII complex, where it can function
as a tethering factor and/or auxiliary motor driving transcription.
Lastly, we have revealed how MVI interacts with nuclear recep-
tors with the potential to modulate gene expression.
Methods
Constructs. A list of constructs and PCR primers are provided in Supplementary
Tables 5 and 8, respectively. Human MVITAIL and NMVITAIL were generated using
directional TOPO cloning in to pET151 using pEGFP-NI-MVI as a template. The
CBD, NCBD1060-1120 and CCBD1121-1253 were isolated by PCR using pET151
MVITAIL as a template, restriction digested by NheI and NotI and cloned into
pET28. MVITAIL (large insert) and CBD (large insert) were cloned by PCR and
restriction digestion using NheI and NotI in to pET28 using pEGFP-C3-LI-MVI as
a template. CBD M1062Q (large insert) was cloned in the same manner from
pEGFP-C3-LI-MVI M1062Q. CBD ΔSite A was cloned as above from pEGFP-C3-
NI-MVI WKSKNKKR/WASANNNR. MVI, Motor1-814 and Motor1-1060 were
cloned by PCR and restriction digest (NotI and XhoI) into pFastbacHTB using
pFastbacHTB-NI-GFP-MVI as template. pET28 calmodulin was cloned by PCR
and restriction digestion from pFastbac1calmodulin.
Modiﬁed CBD and MVITAIL constructs were made by site-directed mutagenesis
using standard Quick-Change site-directed mutagenesis protocol. All plasmids
were veriﬁed by DNA sequencing.
The dual-labelled full-length myosin VI construct was generated by restriction
digest of pEGFP-NI-MVI with XcmI (within MVI) and SacII (in vector) to remove
the last 67 residues at the C terminus of myosin VI. A synthetic gene was produced
(pMXMVI C terminus) containing the C terminus with both cut sites but mRFP
was introduced prior to the SacII site. The construct was then assembled to yield FL
pEGFP-NI-MVI-RFP.
Protein expression and puriﬁcation in Escherichia coli. Recombinant constructs
were expressed in E.coli BL21 DE3 cells (Invitrogen) in Luria Bertani media.
Proteins were puriﬁed by afﬁnity chromatography (HisTrap FF, GE Healthcare).
The purest fractions were desalted through a PD10 column (GE Healthcare) to
remove imidazole before treatment with TEV protease for 4 h at 25 °C. The
samples were then passed through a second HisTrap column. The cleaved protein
was further puriﬁed through a Superdex 200 16/600 column (GE Healthcare).
Note: TEV cleavage was not performed when the His-tag was needed for pull-down
experiments.
Protein expression using baculovirus system. Full-length myosin VI, Motor1-
814, Motor1-1060 and Xenopus calmodulin were expressed in Sf9 and Sf21 (Spo-
doptera frugiperda) insect cells using the Baculovirus expression system. Sf9 cells
were cultured in suspension in sf900 media (Gibco) at 27 °C to generate the P1-3
recombinant baculovirus stocks. Finally, expression of recombinant proteins was
set up by infecting sf21 cells with the P3 viral stock in ExCell 420 media (Sigma).
The cells were harvested by centrifugation for protein puriﬁcation after 4 days.
Prior to sonication, an additional 5 mg Calmodulin was added with 2 mM DTT.
After sonication, 5 mM ATP and 10mM MgCl2 were added and the solution was
rotated at 4 °C for 30 min before centrifugation (20,000 × g, 4 °C, 30 min). Then,
the cell lysate was subjected to the puriﬁcation steps described above.
Protein labelling. Proteins were transferred into 50 mM Na-phosphate (pH 6.5)
using a PD10 column. Samples were then incubated with a 5-fold excess of dye for
4 h, rotating at 4 °C. Excess dye was removed using a PD10 column pre-
equilibrated with 50 mM Na-Phosphate, 150 mM NaCl and 1 mM DTT. Labelling
efﬁciency was calculated based on the absorbance at 280 nm and the absorbance
maximum of the dye. Typical efﬁciency was 90%, whereby the less than complete
labelling was taken as an indicator for a single dye per protein. This was tested for
isolated preparations in mass spectroscopy, which revealed both an unlabelled and
single labelled population.
Cell culture and transfection. HeLa (ECACC 93021013) and MCF7 (ECACC
86012803) cells were cultured at 37 °C and 5% CO2, in Gibco MEM Alpha medium
with GlutaMAX (no nucleosides), supplemented with 10% Fetal Bovine Serum
(Gibco), 100 units per ml penicillin and 100 µg ml−1 streptomycin (Gibco). For the
transient expression of MVI isoforms, HeLa cells grown on glass coverslips were
transfected with EGFP-NI-MVI, EGFP-LI-MVI and EGFP-LI-MVI(M1062Q)
constructs using Lipofectamine 2000 (Invitrogen), following the manufacturer’s
instructions. At 72 h post transfection, cells were subjected to nuclear staining,
ﬁxed and analysed or subjected to indirect immunoﬂuorescence (see below). For
MVI knock-down experiments, MCF7 monolayers, seeded to 30–50% conﬂuency,
were transfected with human myosin VI siRNA duplex (5′-GGUUUAGGU-
GUUAAUGAAGtt-3′) (Ambion) or AllStars Negative Control siRNA duplex
(Qiagen) at a concentration of 50 nM, using Lipofectamine 2000 (Invitrogen),
according to the manufacturer’s guidelines. Cells were harvested after 48 h for
immunoblot and RT-qPCR analysis.
Nuclei isolation. The nuclei isolation protocol was adapted from the Collas Lab
protocol42. HeLa cells were washed once with ice-cold PBS, then washed in ice-cold
Hypotonic Buffer N (10 mM Hepes pH 7.5, 2 mM MgCl2, 25 mM KCl supple-
mented with 1 mM PMSF,1 mM DTT and 1x Halt Protease Inhibitor Cocktail
(Thermo Fisher Scientiﬁc)). Cells well then re-suspended in ice-cold hypotonic
buffer N and incubated for 1 h on ice. Cells were then homogenised on ice with a
glass Dounce homogeniser (Wheaton). Cell lysate was supplemented with 2 M
sucrose solution and mixed well by inversion before centrifugation. The super-
natant which corresponded to the cytoplasmic fraction, was aliquoted and stored at
−80 °C. The pellet, which corresponded to isolated nuclei, was further cleaned by
washing in ice-cold buffer N (10 mM Hepes pH 7.5, 2 mM MgCl2, 25 mM KCl,
250 mM sucrose, supplemented with 1 mM PMSF, 1 mM DTT and 1x Halt Pro-
tease Inhibitor Cocktail). The nuclei pellet was re-suspended either in ice-cold
Buffer N and used immediately or in freezing medium (70% glycerol in buffer N),
to yield a concentration of 4 × 106 nuclei per ml. Nuclei were aliquoted on ice and
stored at −80 °C.
Nuclear staining and immunoﬂuorescence. Puriﬁed fresh or defrosted nuclei
were immobilised on Poly-D-lysine (MW 70,000–150,000, Sigma)-coated glass
coverslips (ThermoFisher) by 30 min incubation at 37 °C. Glass coverslips were
coated with 0.1 mg ml−1 Poly-D-lysine solution in H2O, for 30 min, at room tem-
perature, washed and dried. Immobilised nuclei were stained with 1 μg ml−1
Hoechst 33342 (ThermoFisher) and/or 5 μl ml−1 Vybrant® DiD Cell-Labeling
Solution (ThermoFisher) in Buffer N. Transfected and non-transfected HeLa cells
grown on glass coverslips were incubated for 10 min at 37 oC with 1 μg ml−1
Hoechst 33342 in growth medium. Stained cells or nuclei were ﬁxed for 15 min at
room temperature in 4% (w/v) paraformaldehyde (PFA) and residual PFA was
quenched for 15 min with 50 mM ammonium chloride. All subsequent steps were
performed at room temperature. Cells or nuclei were permeabilised and simulta-
neously blocked for 15 min with 0.1 % (v/v) Triton X-100 and 2 % (w/v) BSA in
TBS. Cells or nuclei were then immune-stained against the endogenous proteins by
1 h incubation with the indicated primary and subsequently the appropriate
ﬂuorophore-conjugated secondary antibody (details below), both diluted in 2% (w/
v) BSA in TBS. The following antibodies were used at the indicated dilutions:
Rabbit anti-MVI (1:200, Atlas-Sigma HPA0354863-100UL), mouse-NDP52 (1:200,
Abcam Ab124372), rabbit anti-RNAPII phospho S5 (1:500, Abcam Ab5131),
donkey anti-mouse Alexa Fluor 647-conjugated (1:500, Abcam Ab150103) and
donkey anti-rabbit Alexa Fluor 555-conjugated antibody (1:500, Abcam
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Ab150074). For actin staining, ﬁxed and permeabilised cells or nuclei were stained
prior to immunoﬂuorescence with 165 nM Rhodamine-Phalloidin (ThermoFisher)
for 20 min. Coverslips were mounted on microscope slides with Mowiol (10% (w/
v) Mowiol 4–88, 25% (w/v) glycerol, 0.2 M Tris-HCl, pH 8.5), supplemented with
2.5% (w/v) of the anti-fading reagent DABCO (Sigma).
For colocalisation analysis, ROIs were drawn around the nuclei of individual
cells, or around whole cells in the case of Fig. 4g and Supplementary Fig. 5c (5 cells
and 5 stacks per cell). Pearson’s coefﬁcients were obtained with the JACoP plugin43
for ImageJ.
Immunoblot analysis. The total protein concentration of the cytoplasmic and
nuclei fraction was determined by Bradford Assay (Sigma) following the manu-
facturer’s instructions. Nuclei, cytoplasmic fractions and cell lysates were heat-
denatured and resolved by SDS-PAGE. The membrane was probed against the
endogenous proteins by incubation with the indicated rabbit polyclonal primary
and subsequently a goat anti-rabbit antibody coupled to horseradish peroxidase
(1:15,000 Abcam Ab6721). The following primary antibodies were used at the
indicated dilutions: Rabbit anti-MVI (1: 500, Atlas-Sigma HPA0354863-100UL),
Rabbit anti-NDP52 (1:2000, GeneTex GTX115378), Rabbit anti-alpha tubulin
(1:1000, Santa Cruz sc5286), Rabbit anti-Lamin B (1:1000, Abcam ab16048 and
rabbit anti-RNAP II phospho S5 (1:1000, Abcam Ab5131). The bands were
visualised using the ECL Western Blotting Detection Reagents (Invitrogen) and the
images were taken using Syngene GBox system. Images were processed in ImageJ.
Uncropped blots are shown in Supplementary Figs. 9 and 10.
Co-immunoprecipitation. Immunoprecipitation was performed using rabbit anti-
myosin VI (Sigma), or rabbit anti-NDP52 (Genetex). Antibodies were bound to
Protein A and G dynabeads, respectively, according to the manufacturer’s
instructions. Immunoprecipitation was performed from total protein extract for 2 h
in a buffer containing 50 mM Tris-HCl, 150 mM NaCl, 1 mM DTT, 1 mM PMSF
and 1% Triton X-100. Samples were subjected to immunoblot for RNAPII, as
described above. Where samples were compared between conditions, equal total
protein concentrations were used.
Imaging. Cells and nuclei were visualised using Olympus IX71 microscope with
PlanApo 100xOTIRFM-SP 1.49 NA lens mounted on a PIFOC z-axis focus drive
(Physik Instrumente, Karlsruhe, Germany), and illuminated with an automated
300W Xenon light source (Sutter, Novato, CA) with appropriate ﬁlters (Chroma,
Bellows Falls, VT). Images were acquired using a QuantEM (Photometrics)
EMCCD camera, controlled by the Metamorph software (Molecular Devices). The
whole volume of cells and nuclei was imaged by acquiring images at z-steps of 200
nm. Using the Hoechst 33342 staining, the lower and upper sections at which the
nucleus was in focus were deﬁned. Unless stated otherwise, images presented here
correspond to a middle section between these two limits, which ensures imaging
within the nucleus. Images were deconvolved with the Autoquant X software
applying blind deconvolution and analysed by ImageJ.
FLIM sample preparation and data acquisition. Transfections were performed as
above with the exception that 1 mgml−1 sodium borohydride (Sigma) was used for
quenching. All time correlated single photon counting mode (TCPSC) images were
acquired using the custom-built multifocal multiphoton ﬂuorescence lifetime
imaging system (MM-FLIM) as described previously44. In brief, light generated
from a Chameleon Ultra II Ti:Sapphire laser source (Coherent Inc.) is coupled with
a spatial light modulator (SLM) to generate a uniform 8 × 8 array of beamlets. This
beamlet array is then relayed through a set of galvanometer scanners (providing x–
y raster scanning capability) onto the back-pupil plane of a 40 × 1.3 N.A. Plan Fluor
oil objective (Nikon) where it is projected onto the sample. The two-photon
generated ﬂuorescence is collected and descanned where it is directed with a
dichroic mirror and focused onto the Megaframe SPAD array using a 10 × 0.3 N.A.
Plan Fluor air objective (Nikon).
For each individual image acquisition, the system processed 64 × 64 data points
for 8 × 8 detectors producing 512 × 512 pixel images. Lifetime data was acquired
operating the Megaframe camera in TCPSC mode. In TCSPC mode, on-pixel
TDCs generate raw time-correlated data, which are stored and then post-processed
ofﬂine to generate an image. Full details on TCSPC data acquisition can be found
in ref. 44. Once processed, these data are saved and then subsequently analysed
using TRI2 lifetime analysis software45.
RNA extraction and RT-qPCR. RNA from MCF7 cells transfected with MVI or
siRNA and negative control duplexes was extracted using Gene Jet RNA pur-
iﬁcation kit (Thermo scientiﬁc) according to the manufacturer’s protocol. The
RNA concentration was measured using Geneﬂow Nanophotometer and RT-qPCR
was performed with one-step QuantiFast SYBR Green qPCR kit (Qiagen) using 50
ng of RNA in each sample. A list of qPCR primers is given in Supplementary
Table 6.
Dual-luciferase assay. MCF7 cells were seeded in a 24-well plate at a density of
1.0 × 105cells per well in no phenol red MEM media (Gibco) with 5% double
charcoal stripped FCS (First Link UK) and 1% Penicillin-Streptomycin. After 48 h
of starvation, the cells were co-transfected with 3X-ERE-TATA-Luc expression
plasmid (400 ng per well), RL-CMV plasmid (400 ng per well) and human myosin
VI siRNA duplex (5′-GGUUUAGGUGUUAAUGAAGtt-3′) (Ambion) or AllStars
Negative Control siRNA duplex (Qiagen) at a concentration of 50 nM, using
Lipofectamine 2000 (Invitrogen), according to the manufacturer’s guidelines. In the
control wells, cells were co-transfected with 3X-ERE-TATA-Luc and RL-CMV
expression plasmids only. After 24 h of transfection, cells were treated with 10 nM
of Estradiol or vehicle control and the luciferase activity was measured the fol-
lowing day using Dual-Glo luciferase reporter assay kit (Promega). Levels of ﬁreﬂy
luciferase were standardised to those of Renilla. All samples were measured in
triplicates.
DNA substrates. Labelled and unlabelled oligonucleotides were purchased from
Sigma-Aldrich. To form duplex DNA substrates, oligonucleotides were mixed at
equimolar concentrations at either 50 μM in water or a buffer containing 50 mM
Tris.HCl at pH 7.5, 150 mM NaCl, and 3 mM MgCl2. A list of DNA substrates is
given in Supplementary Table 7.
In vitro transcription. The DNA template was the pEGFP-C3 linearised plasmid
containing the CMV promoter that would generate a 130-base run-off transcript.
The HelaScribe (Promega) reactions were performed in triplicates, through two
independent experiments, according to the manufacturer’s instructions. The
reactions were performed for 60 min at 25 °C.
Reactions were also performed following pre-clearance with the stated
antibodies. Protein G or A Dynabeads (Invitrogen) were prepared according to the
manufacturer’s instructions before being loaded with 4 μg antibody. Samples were
incubated for 30 min on ice and beads were extracted immediately before
performing the transcription reaction.
For quantiﬁcation, mRNA was puriﬁed using Gene Jet RNA puriﬁcation kit
(Thermo Scientiﬁc) according to the manufacturer’s protocol and RT-qPCR was
performed with one-step QuantiFast SYBR Green qPCR kit (Qiagen).
Preparation of liposomes. Mixed brain liposomes—Folch fraction 1 (Sigma) were
re-suspended in 20 mM HEPES (pH 7.4), 150 mM NaCl and 1 mM DTT to a ﬁnal
concentration of 1 mgml−1. The mixture was then extruded using a 100 nm ﬁlter.
Liposomes were stored at 4 °C and used within 4 days.
Actin-pelleting assay. The assay was modiﬁed from Morriswood et al. Full length
MVI was incubated with the tail construct at the speciﬁed concentrations in
reaction buffer (150 mM NaCl, 50 mM Tris HCl (pH 7.5), 1 mM MgCl2 and 1 mM
DTT), for 30 min at 4 °C. 5 μM F-actin (from M. Geeves) was added to the mixture
before centrifugation at 190,000 × g for 15 min at 4 °C. The pellet was re-suspended
in 50 μl reaction buffer and samples were analysed by SDS-PAGE and densitometry
using ImageJ.
Protein–protein and protein–DNA isolation. His-tagged protein–protein pull
downs. 10 μM His-tagged bait protein was bound to His Mag Sepharose Ni beads
(GE Healthcare) according to the manufacturer’s instructions. Samples were
incubated in 50 mM Tris-HCl (pH 7.5), 500 mM NaCl and 40 mM imidazole and
1 mM DTT for 30 min shaking (400 rpm) at 25 °C. Beads were isolated and
samples volumes were normalised with NuPAGE Sample buffer before SDS-PAGE.
Pull-down from nuclear extract. His-tagged bait protein was prepared as above.
Frozen nuclei aliquots were defrosted as described above and re-suspended in 50
mM Tris-HCl (pH 7.5), 500 mM NaCl and 40 mM imidazole, 1 mM DTT and 1%
Triton X. Nuclei were incubated on ice for 15 min for lysis to occur. Samples were
then incubated for 30 min as above before proceeding with immunoblot analysis.
GST-tagged protein–protein. 10 μM GST-tagged bait protein was bound to
glutathione sepharose resin (GE Healthcare) according to the manufacturer’s
instructions. Samples were incubated in PBS supplemented with 1 mM DTT,
shaking at 25 °C for 30 min. Beads were isolated by centrifugation (1000 × g for 5
min) and samples volumes were equalised with NuPAGE sample buffer before
SDS-PAGE.
DNA protein. A single biotin labelled 500 bp DNA substrate was generated by
PCR with 5′ biotin-TEG primer using pSG1365 as a template. Free biotin primers
were removed using a QiaQuick PCR puriﬁcation kit (Qiagen). 1 mg Streptavidin
Dynabeads (M-280) (Invitrogen) were washed three times in wash buffer (10 mM
Tris-HCl pH 7.5, 1 mM EDTA and 2M NaCl). 1 μg DNA was added in an equal
volume to bring the ﬁnal NaCl concentration to 1M and incubated for 15 min at
room temperature. Beads were washed three times in wash buffer before re-
suspension in binding buffer (50 mM Tris-HCl pH 7.5, 3 mM MgCl2, 1 mM DTT
and 50 mM NaCl). Protein was added to the beads and incubated shaking (400
rpm) for 30 min, at 25 °C. Beads were extracted and samples volumes were
normalised with NuPAGE sample buffer before SDS-PAGE.
Gliding ﬁlament assays. Motility assays were performed at 30 °C. Antibody
immobilisation was achieved using rabbit anti-myosin VI (Atlas-Sigma
HPA0354863-100UL) against the C terminus that was pre-absorbed to
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nitrocellulose (0.1% v/v). NDP52 immobilisation was achieved by ﬂowing 0.1, 0.5
or 1 μM NDP52 onto nitrocellulose. Subsequently, 100 µg ml−1 MVI was added to
the ﬂow cells in 50 mM Tris-HCl (pH 7.5), 20 mM Imidazole, 1 mM EGTA, 5 mM
MgCl2 and 5 mM DTT. TRITC-phalloidin-labelled actin ﬁlaments were added in
the same buffer plus oxygen scavenger (5 Uml−1 Glucose oxidase and 800 Uml−1
Catalase) and 2 mM ATP. Filaments were visualised every 5 s for a total period of
500 s. Individual trajectories were tracked and velocities extracted using GMimPro
(www.mashanov.uk).
Steady-state ATPase activity of MVI. Ca2+-actin monomers were converted to
Mg2+-actin with 0.2 mM EGTA and 50 μM MgCl2 before polymerising by dialysis
into 20 mM Tris-HCl (pH 7.5), 20 mM imidazole (pH 7.4), 25 mM NaCl and 1 mM
DTT. A 1.1 molar equivalent of phalloidin (Sigma) was used to stabilise actin
ﬁlaments.
Steady-state ATPase activities were measured at 25 °C in KMg50 buffer (50 mM
KCl, 1 mM MgCl2, 1 mM EGTA, 1 mM DTT, and 10 mM imidazole, pH 7.0).
Supplemented with the NADH-coupled assay components, 0.2 mM NADH, 2 mM
phosphoenolpyruvate, 3.3 Uml−1 lactate dehydrogenase, 2.3 Uml−1 pyruvate
kinase and various actin concentrations (0–30 μM). The ﬁnal [Mg.ATP] was 5 mM
and MVI concentration was 100–300 nM. The assay was started by the addition of
MVI. The change in absorption at OD340 nm was followed for 5 min. The kcat and
Kactin values were determined by ﬁtting the data .
Rate ¼ Vo þ
kcat½Actin
Kactin þ ½Actin
 
Vo is the basal ATPase activity of MVI, kcat is the maximum actin-activated ATPase
rate and Kactin is the concentration of actin needed to reach half maximal ATPase
activity.
Stopped ﬂow measurements. A HiTech SF61DX2 apparatus (TgK Scientiﬁc Ltd,
Bradford-on-Avon, UK) with a mercury-xenon light source and HiTech Kinetic
Studio 2 software was used46–50. Anisotropy was measured with the instrument in
the ‘T’ format, allowing simultaneous acquisition of horizontal (I//) and perpen-
dicular (I⊥) components. This enabled anisotropy (I// − I⊥)/(I// + 2I⊥), and intensity
(I// + 2I⊥) to be calculated from the same set of data. The G-factor was accounted
for by normalising the detectors prior to performing measurements. Excitation was
at 495 nm with emission through a 515 nm cut-off ﬁlter (Schott Glass). In all
experiments, the quoted concentrations are those in the mixing chamber, except
when stated. All experiments were performed at 25 °C in 50 mM Tris-HCl, 150
mM NaCl, 1 mM DTT and 3mM MgCl2. The dead time of the stopped-ﬂow
instrument was ~2 ms: during this initial time no change in ﬂuorescence can be
observed.
Titration measurements. All reactions were performed at 25 °C in a buffer con-
taining 50 mM Tris·HCl (pH 7.5), 150 mM sodium chloride and 1 mM DTT in a
ﬁnal volume of 100 μl. Measurements were performed using a ClarioStar Plate
Reader (BMG Labtech) with the exception of the tryptophan measurements which
were performed in a Cary Spectrophotometer (Varian).
Intensity measurements were performed at the following wavelengths:
Tryptophan (ex. 295 nm), GFP (ex. 490 nm), RFP (ex. 585 nm), FITC (ex. 490 nm),
Alexa Fluor 555 (ex. 555 nm). FITC to Alexa Fluor 555 FRET measurements were
performed using the following wavelengths ex. 470 nm and em. 575 nm.
Anisotropy was measured with the instrument in the T format, allowing
simultaneous acquisition of parallel (I//) and perpendicular (I┴) components using
BMG ﬁlter-sets for ﬂuorescein (Ex. 482/16-10, Dichroic LP504 and em. 530/-40).
Analysis of kinetic data. For ﬂuorescence anisotropy titrations: anisotropy was
calculated, as described below, based upon established procedures46, 47, 51, 52.
Total ﬂuorescence intensity (Ft) is given by:
Ft ¼
X
ciFi
Total anisotropy (At) is given by:
At ¼
P
ciFiAi
Ft
Where ci is the concentration of species i, Fi is the ﬂuorescence intensity per unit of
concentration and Ai is the anisotropy. This is calculated from the parallel and
perpendicular ﬂuorescence intensity (I) in relation to the plane of excitation by:
Ai ¼
Iparallel  Iperpendicular
Iparallel þ 2Iperpendicular
As anisotropy is additive for multiple ﬂuorescence species in solution, it is used
to give a measure of their relative concentrations. For MVI (and various constructs)
there are two ﬂuorescence species, DNA and MVI.DNA. The total anisotropy can
then be calculated in terms of the dissociation constant (Kd) for the MVI.DNA
complex:
At ¼
ADNA ½DNAt  ½MVI:DNA
 
þ AMVI:DNAQ½MVI:DNA
½DNAt  ½MVI:DNA þ Q½MVI:DNA
where
½MVI:DNA ¼
½MVIt þ ½DNAt þ Kd
 

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
½MVIt þ ½DNAt þ Kd
 2
 4½MVIt½DNAt
q
2
And where [MVI]t and [DNA]t are the total concentrations for each reactant.
[MVI.DNA] is the concentration of the protein-bound DNA complex. Q is the
ﬂuorescence intensity of MVI.DNA relative to DNA. The anisotropy data were
ﬁtted to obtain dissociation constants based on the above equations using GraFit
ﬁtting software53.
For the FRET titrations: the 575 nm intensity data were corrected for the
increase in intensity due to a small direct excitation. This background signal was
subtracted from the dataset to leave the FRET values. The titration curves for the
MVITAIL interactions were ﬁtting to a binding quadratic equation:
½Complex ¼
½FITCt þ ½AF555t þ Kd
 

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
½FITCt þ ½AF555t þ Kd
 2
 4½FITCt½AF555t
q
2
For lipid titrations: curves were ﬁtted to a 1 site plus background equation:
½Fluorescence ¼
Amplitude:½Lipid
Kd þ ½Lipid
þ Background
Data availability. The data supporting the ﬁndings of this study are available from
the corresponding author on request.
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